Albireo Pharma (ALBO) Set to Announce Quarterly Earnings on Thursday

Albireo Pharma (NASDAQ:ALBO) will release its earnings data before the market opens on Thursday, May 9th. Analysts expect Albireo Pharma to post earnings of ($1.37) per share for the quarter.

Albireo Pharma (NASDAQ:ALBO) last announced its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.18). Albireo Pharma had a negative return on equity of 32.42% and a negative net margin of 361.94%. The business had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $1.94 million. On average, analysts expect Albireo Pharma to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Shares of ALBO opened at $36.20 on Tuesday. Albireo Pharma has a fifty-two week low of $19.10 and a fifty-two week high of $37.95. The company has a market capitalization of $437.75 million, a PE ratio of -9.19 and a beta of 1.72.

Several brokerages have recently weighed in on ALBO. BidaskClub raised shares of Albireo Pharma from a “buy” rating to a “strong-buy” rating in a research report on Friday. ValuEngine raised shares of Albireo Pharma from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 26th. Cowen reaffirmed a “buy” rating on shares of Albireo Pharma in a research report on Wednesday, April 17th. Zacks Investment Research cut shares of Albireo Pharma from a “hold” rating to a “sell” rating in a research report on Monday, March 11th. Finally, Wedbush set a $69.00 price target on shares of Albireo Pharma and gave the stock a “buy” rating in a research report on Sunday, March 10th. One analyst has rated the stock with a sell rating, four have issued a buy rating and two have issued a strong buy rating to the company’s stock. Albireo Pharma has an average rating of “Buy” and a consensus target price of $54.25.

A hedge fund recently raised its stake in Albireo Pharma stock. Geode Capital Management LLC increased its position in shares of Albireo Pharma Inc (NASDAQ:ALBO) by 11.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 97,434 shares of the biopharmaceutical company’s stock after acquiring an additional 9,922 shares during the quarter. Geode Capital Management LLC owned about 0.81% of Albireo Pharma worth $2,390,000 as of its most recent SEC filing. Institutional investors and hedge funds own 66.91% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Albireo Pharma (ALBO) Set to Announce Quarterly Earnings on Thursday” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at

About Albireo Pharma

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Featured Article: Bull Market

Earnings History for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with's FREE daily email newsletter.